跳至主要内容
临床试验/NCT00364572
NCT00364572已完成1 期

Efficacy of Epidural Etanercept in the Treatment of Sciatica

Johns Hopkins University1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2006年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
24
试验地点
1
主要终点
Visual analogue scale pain score, Oswestry disability index, medication intake

研究概览

简要总结

Tumor necrosis factor (TNF)-alpha has been strongly implicated as a major contributing factor for the development of radiculopathy. In animal studies, the application of TNF-alpha to nerve roots results in pain behavior indicative of radiculopathy. The use of TNF-alpha inhibitors (etanercept and infliximab) have been shown to prevent this pain behavior. Open-label studies in humans have shown both etanercept and infliximab provide excellent, long-term relief in patients with acute radiculopathy from herniated disc. However, a recent placebo-controlled study failed to demonstrate any significant difference from placebo. The investigators have already established the safety of neuraxial etanercept in a trial that has just been completed (not yet published). The objective of this study is to determine whether small doses of epidural etanercept, an anti-TNF-a medication, is an effective treatment for LBP caused by nerve root irritation (i.e., radiculopathy).

详细描述

As per the wishes of the Dept. of the Army and Walter Reed Army Medical Center Dept. of Clinical Investigation, patients will be randomized in a 3:1 ratio to receive 2 transforaminal epidural etanercept or saline injections at 2-week intervals. Both patients and physicians will be blinded as to the injectate and treatment group. There will be 3 study groups. Group I will receive either 2 mg of etanercept or saline per injection. Group II will receive either 4 mg of etanercept or saline per injection. Group III will receive either 6 mg of etanercept or saline per injection. In each group there will be 8 patients: 6 who receive etanercept and 2 who receive saline. As per a previous study we just completed, etanercept doses will not be escalated until all 6 patients have completed their 1-month follow-up visits without any evidence of toxicity or complications.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Chronic low back pain of radicular origin of > 2 months but < 1 year duration.
  • Failure of conservative therapy to include physical and pharmacotherapy.
  • MRI evidence of a herniated disc corresponding to the patient's radicular symptoms.
  • Normal white blood cell count (drawn in 1 blood vial).

排除标准

  • Uncontrolled coagulopathy.
  • Pregnancy, which will be ruled out by a urine pregnancy test if any question as to the patient's status exists.
  • Allergy to contrast dye.
  • Unstable medical condition (e.g., unstable angina or congestive heart failure).
  • Rheumatoid arthritis, Crohn's disease or spondylarthropathy.
  • Unstable neurological condition (e.g., multiple sclerosis)
  • Systemic infection
  • Age < 18 or > 70 years.

研究组 & 干预措施

1

Placebo Comparator

Two injections of epidural saline 2 weeks apart

干预措施: placebo (control procedure) (Drug)

Epidural injection of etanercept

Experimental

Two injections of epidural etanercept 2 weeks apart

干预措施: epidural injection of etanercept (Drug)

结局指标

主要结局

Visual analogue scale pain score, Oswestry disability index, medication intake

时间窗: 7 months

次要结局

  • Global perceived effect, white blood cell count(7 months)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Efficacy of Epidural Etanercept in the Treatment of... | 临床试验